Degarelix 240/80 mg: A new treatment option for patients with advanced prostate cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 12, 2009, Pages 1737-1743

  Boccon Gibod, Laurent ^a   Iversen, Peter ^b   Persson, Bo Eric ^c  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Ferring Pharmaceuticals AS   (Denmark)

Author keywords

Androgen deprivation therapy; Degarelix; Gonadotrophin releasing hormone; Leuprolide; Prostate cancer; Prostate specific antigen; Testosterone

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DEGARELIX; FIRMAGON; GONADORELIN ANTAGONIST; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; CHILL; CLINICAL TRIAL; CONSTIPATION; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLUSHING; FOOD AND DRUG ADMINISTRATION; GLEASON SCORE; HORMONE INHIBITION; HOT FLUSH; HUMAN; HYPERTENSION; INJECTION SITE REACTION; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; URINARY TRACT INFECTION; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROSTATIC NEOPLASMS;

EID: 73349112557     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.150     Document Type: Review

References (23)

1. Fleming MT, Morris MJ, Heller G, Scher HI. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat. Clin. Pract. Oncol. 3(12), 658-667 (2006).
2. Lilja H, Ulmert D, Vickers AJ. Prostatespecific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 8(4), 268-278 (2008).
3. Conn PM, Crowley WF Jr. Gonadotropinreleasing hormone and its analogues. N. Engl. J. Med. 324(2), 93-103 (1991).
4. Lepor H. Comparison of single-agent androgen suppression for advanced prostate cancer. Rev. Urol. 7(Suppl. 5), S3-S12 (2005).
5. Yri OE, Bjoro T, Fossa SD. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur. Urol. 49(1), 54-58 (2006).
6. Anderson J, Abrahamsson PA, Crawford D, Miller K, Tombal B. Management of advanced prostate cancer: can we improve on androgen deprivation therapy? BJU. Int. 101(12), 1497-1501 (2008). Describes the utility and shortcomings of gonadotrophin-releasing hormone (GnRH) agonist therapy in prostate cancer and highlights the differences in pharmacological profile between GnRH agonists and blockers.
7. Waxman J, Man A, Hendry WF et al. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br. Med. J. (Clin. Res. Ed.) 291(6506), 1387-1388 (1985).
8. Boccon-Gibod L, Laudat MH, Dugue MA, Steg A. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate. Eur. Urol. 12(6), 400-402 (1986).
9. Thompson IM, Zeidman EJ, Rodriguez FR. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J. Urol. 144(6), 1479-1480 (1990).
10. Van Poppel H, Nilsson S. Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 71(6), 1001-1006 (2008). Describes the GnRH agonist-induced testosterone surge and its clinical consequences, and highlights the differences in pharmacological profile between GnRH agonists and blockers.
11. Balchen T, Agersø H, Olesen TK, Jensen JK, Senderovitz T. Pharmacokinetics, pharmacodynamics, and safety of a novel fast-acting gonadotropinreleasing hormone receptor blocker, degarelix, in healthy men. Presented at: 8th International Symposium on GnRH Analogues in Cancer and Human Reproduction Salzburg, Austria 10-13 February (2005).
12. Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK. A 1-year, open label, randomized Phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J. Urol. 180(5), 1986-1992 (2008). Together with the study in [13], this study identified the degarelix dose regimens to be tested in the Phase III trial and demonstrated that 1-year degarelix treatment resulted in a fast, profound and sustained suppression of testosterone and prostate-specific antigen (PSA) with no evidence of testosterone surge.
13. Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold OT. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, Phase 2 dosage-finding study in the treatment of prostate cancer. Eur. Urol. 54(4), 805-813 (2008). Together with the study in [12], this study identified the degarelix dose regimens to be tested in the Phase III trial and demonstrated that 1-year degarelix treatment resulted in a fast, profound and sustained suppression of testosterone and PSA with no evidence of testosterone surge.
14. Klotz L, Boccon-Gibod L, Shore ND et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group Phase III study in patients with prostate cancer. BJU Int. 102(11), 1531-1538 (2008). Demonstrates that degarelix is as effective as leuprolide over 1-year prostate cancer treatment in terms of inducing and maintaining testosterone suppression and that it achieves a more rapid suppression of testosterone and PSA than leuprolide, without testosterone surge.
15. Persson BE, Kold Olesen T, Jensen JK. Degarelix: a new approach for the treatment of prostate cancer. Neuroendocrinology. 90(3), 235-244 (2009).
16. Morote J, Ruibal A, Palou J, de Torres JA, Soler-Rosello A. Clinical utility of prostatic specific antigen and prostatic acid phosphatase serum levels in monitoring prostate cancer. Int. J. Biol. Markers 3(1), 23-28 (1988).
17. Matzkin H, Lewyshon O, Ayalon D, Braf Z. Changes in prostate-specific markers under chronic gonadotrophinreleasing hormone analogue treatment of state D prostatic cancer. Cancer 63(7), 1287-1291 (1989).
18. Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 76(1), 96-100 (1995).
19. Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostatespecific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J. Clin. Oncol. 16(5), 1835-1843 (1998).
20. Morote J, Orsola A, Planas J et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J. Urol. 178(4 Pt 1), 1290-1295 (2007). Shows that breakthrough increases in plasma testosterone (>32 ng/ml) during GnRH agonist therapy predict reduced survival free of androgen-independent progression. Concomitant antiandrogen treatment provided a significantly longer survival free of androgen-independent progression in those with breakthrough increases greater than 50 ng/dl.
21. Lebret T, Bouregba A. Roles of the urologist and nurse from the perspective of patients with prostate cancer receiving luteinizing hormone-releasing hormone analogue therapy. BJU Int. 102(10), 1419-1424 (2008).
22. US FDA. Cancer drug approval end points for prostate cancer (2009) www.fda.gov/Drugs/ DevelopmentApprovalProcess/ DevelopmentResources/CancerDrugs/ ucm094586.htm
23. Heidenreich A, Bolla M, Joniau S et al. European treatment guidelines for prostate cancer. European Association of Urology (2009) www.uroweb.org/fileadmin/tx-eauguidelines/2009/Full/Prostate-Cancer.pdf